233 related articles for article (PubMed ID: 25066094)
1. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.
Brugière C; Stefan A; Morice C; Cornet E; Moreau A; Allouche S; Verneuil L
Br J Dermatol; 2014 Dec; 171(6):1529-32. PubMed ID: 25066094
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib: an unusual UVA-induced photosensitivity.
Gelot P; Dutartre H; Khammari A; Boisrobert A; Schmitt C; Deybach JC; Nguyen JM; Seité S; Dréno B
Exp Dermatol; 2013 Apr; 22(4):297-8. PubMed ID: 23528218
[TBL] [Abstract][Full Text] [Related]
3. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
[TBL] [Abstract][Full Text] [Related]
4. The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
Woods JA; Ferguson JS; Kalra S; Degabriele A; Gardner J; Logan P; Ferguson J
J Photochem Photobiol B; 2015 Oct; 151():233-8. PubMed ID: 26318280
[TBL] [Abstract][Full Text] [Related]
5. Characterization of vemurafenib phototoxicity in a mouse model.
Boudon SM; Plappert-Helbig U; Odermatt A; Bauer D
Toxicol Sci; 2014 Jan; 137(1):259-67. PubMed ID: 24154489
[TBL] [Abstract][Full Text] [Related]
6. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.
Anforth R; Carlos G; Eiris N; Clements A; Fernandez-Peñas P
Med J Aust; 2015 Jul; 203(1):41-2. PubMed ID: 26126567
[No Abstract] [Full Text] [Related]
7. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
10. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
Boudewijns S; Gerritsen WR; Koornstra RH
BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
13. Ultraviolet A and photosensitivity during vemurafenib therapy.
Dummer R; Rinderknecht J; Goldinger SM
N Engl J Med; 2012 Feb; 366(5):480-1. PubMed ID: 22296092
[No Abstract] [Full Text] [Related]
14. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
15. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
16. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
[TBL] [Abstract][Full Text] [Related]
19. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
Degen A; Völker B; Kapp A; Gutzmer R
Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
[No Abstract] [Full Text] [Related]
20. Interplay Between Membrane Lipid Peroxidation and Photoproduct Formation in the Ultraviolet A-Induced Phototoxicity of Vemurafenib in Skin Keratinocytes.
Teixeira A; Morlière P; Ferreira J; Conte MA; Galmiche A; Mazière JC; Santus R; Filipe P
Toxicol Sci; 2016 Dec; 154(2):289-295. PubMed ID: 27566444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
